Despite their low frequency, CRC cells with amplification of the MET gene also contribute to primary or secondary resistance to anti-EGFR therapy, as HGF can activate RTK signaling in parallel with EGF8,24,26. The gene discussed is MET; the disease is colorectal carcinoma.